Merck’s remigromig meets non-inferiority goal in DME trial

🌐 Investing.com (Cyprus) —
Merck’s remigromig meets non-inferiority goal in DME trial

AI Summary

Merck's remigromig met the non-inferiority goal in a trial for diabetic macular edema (DME), according to the headline. The brief does not provide trial results, comparator details, or information about the next development steps.

Health Merck remigromig diabetic macular edema clinical trial non-inferiority

Read original source →